

Trastuzumab in the Treatment of Breast Cancer

BioDrugs

30, 75-86

DOI: [10.1007/s40259-016-0162-9](https://doi.org/10.1007/s40259-016-0162-9)

Citation Report

#	ARTICLE	IF	CITATIONS
1	DeBouganin Diabody Fusion Protein Overcomes Drug Resistance to ADCs Comprised of Anti-Microtubule Agents. <i>Molecules</i> , 2016, 21, 1741.	1.7	6
2	The efficient elimination of solid tumor cells by EGFR-specific and HER2-specific scFv-SNAP fusion proteins conjugated to benzylguanine-modified auristatin F. <i>Cancer Letters</i> , 2016, 381, 323-330.	3.2	36
3	Targeted Covalent Inhibition of Grb2â€ˆSos1 Interaction through Proximity-Induced Conjugation in Breast Cancer Cells. <i>Molecular Pharmaceutics</i> , 2017, 14, 1548-1557.	2.3	32
4	Identification of Genomic Somatic Variants in Cancer. <i>Advances in Clinical Chemistry</i> , 2017, 78, 123-162.	1.8	2
5	Reactivation of dormant anti-tumor immunity â€ˆ a clinical perspective of therapeutic immune checkpoint modulation. <i>Cell Communication and Signaling</i> , 2017, 15, 5.	2.7	34
6	Fluorine-18 Labeling of the HER2-Targeting Single-Domain Antibody 2Rs15d Using a Residualizing Label and Preclinical Evaluation. <i>Molecular Imaging and Biology</i> , 2017, 19, 867-877.	1.3	54
7	Targeting proinflammatory cytokines, oxidative stress, TGF-Î²1 and STAT-3 by rosuvastatin and ubiquinone to ameliorate trastuzumab cardiotoxicity. <i>Biomedicine and Pharmacotherapy</i> , 2017, 93, 17-26.	2.5	32
8	Molecular targeted therapy of cancer: The progress and future prospect. <i>Frontiers in Laboratory Medicine</i> , 2017, 1, 69-75.	1.7	150
9	Decoration of trastuzumab with short oligonucleotides: synthesis and detailed characterization. <i>Organic and Biomolecular Chemistry</i> , 2017, 15, 8923-8928.	1.5	6
10	Biological function of long noncoding RNA<i>snar</i> in HER2-positive breast cancer cells. <i>Tumor Biology</i> , 2017, 39, 101042831770737.	0.8	24
11	Combined Analysis of ChIP Sequencing and Gene Expression Dataset in Breast Cancer. <i>Pathology and Oncology Research</i> , 2017, 23, 361-368.	0.9	14
12	Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?. <i>Frontiers in Immunology</i> , 2017, 8, 1245.	2.2	124
13	Targeted therapies in breast cancer: New challenges to fight against resistance. <i>World Journal of Clinical Oncology</i> , 2017, 8, 120.	0.9	227
14	Fundamentals of siRNA and miRNA therapeutics and a review of targeted nanoparticle delivery systems in breast cancer. <i>Biophysical Reviews</i> , 2018, 10, 69-86.	1.5	146
15	Targeting natural compounds against HER2 kinase domain as potential anticancer drugs applying pharmacophore based molecular modelling approaches. <i>Computational Biology and Chemistry</i> , 2018, 74, 327-338.	1.1	34
16	Efficacy and safety of the trastuzumab biosimilar candidate CT-P6. <i>Future Oncology</i> , 2018, 14, 1909-1919.	1.1	9
17	Tumor immunotherapy: New aspects of natural killer cells. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2018, 30, 173-196.	0.7	52
18	Novel treatment strategies for patients with HER2â€ˆpositive breast cancer who do not benefit from current targeted therapy drugs (Review). <i>Experimental and Therapeutic Medicine</i> , 2018, 16, 2183-2192.	0.8	14

#	ARTICLE	IF	CITATIONS
19	Polyethylene glycol-conjugated HER2-targeted peptides as a nuclear imaging probe for HER2-overexpressed gastric cancer detection in vivo. <i>Journal of Translational Medicine</i> , 2018, 16, 168.	1.8	16
20	Precision medicine in relapsed or refractory pediatric solid tumors: a collaborative Spanish initiative. <i>Translational Medicine Communications</i> , 2019, 4, .	0.5	2
21	Advanced nanotechnology: An arsenal to enhance immunotherapy in fighting cancer. <i>Clinica Chimica Acta</i> , 2019, 492, 12-19.	0.5	31
22	A coiled-coil masking domain for selective activation of therapeutic antibodies. <i>Nature Biotechnology</i> , 2019, 37, 761-765.	9.4	55
23	Trastuzumab cotreatment improves survival of mice with PCa prostate cancer xenografts treated with the GRPR antagonist ¹⁷⁷ Lu- DOTAGA -PEG ₂ - RM26 . <i>International Journal of Cancer</i> , 2019, 145, 3347-3358.	2.3	30
24	Hydrodynamic and Electrophoretic Properties of Trastuzumab/HER2 Extracellular Domain Complexes as Revealed by Experimental Techniques and Computational Simulations. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1076.	1.8	5
25	HER2 as a limited predictor of the therapeutic response to neoadjuvant therapy in locally advanced rectal cancer. <i>Pathology Research and Practice</i> , 2019, 215, 910-917.	1.0	4
26	Cost Minimization Analysis of Intravenous or Subcutaneous Trastuzumab Treatment in Patients With HER2-Positive Breast Cancer in Ireland. <i>Clinical Breast Cancer</i> , 2019, 19, e440-e451.	1.1	17
27	Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials. <i>Cancers</i> , 2019, 11, 1826.	1.7	132
28	Novel anti-HER2 peptide-conjugated theranostic nanoliposomes combining NaYF ₄ :Yb,Er nanoparticles for NIR-activated bioimaging and chemo-photodynamic therapy against breast cancer. <i>Nanoscale</i> , 2019, 11, 20598-20613.	2.8	37
29	Antisense Oligonucleotides Targeting Angiogenic Factors as Potential Cancer Therapeutics. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 14, 142-157.	2.3	58
30	A Review of T-Cell Related Therapy for Osteosarcoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4877.	1.8	10
31	Frequency and prognostic value of mutations associated with the homologous recombination DNA repair pathway in a large pan cancer cohort. <i>Scientific Reports</i> , 2020, 10, 20223.	1.6	15
32	Comparative Assessment of Protein Kinase Inhibitors in Public Databases and in PKIDB. <i>Molecules</i> , 2020, 25, 3226.	1.7	40
33	NIR Photodynamic Destruction of PDAC and HNSCC Nodules Using Triple-Receptor-Targeted Photoimmuno-Nanoconjugates: Targeting Heterogeneity in Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 2390.	1.0	20
34	Can precision medicine advance psychiatry?. <i>Irish Journal of Psychological Medicine</i> , 2020, 38, 1-6.	0.7	6
35	Evidence of BK _{Ca} Channelopathy-Driven Breast Cancer Metastasis to Brain. , 0, , .		0
36	Long noncoding RNA MYLK-AS1 promotes growth and invasion of hepatocellular carcinoma through the EGFR/HER2-ERK1/2 signaling pathway. <i>International Journal of Biological Sciences</i> , 2020, 16, 1989-2000.	2.6	12

#	ARTICLE	IF	CITATIONS
37	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 557-588.	8.2	1,155
38	Relationship between CT characteristics and human epidermal growth factor receptor 2 expression in gastric cancers. <i>Chinese Journal of Academic Radiology</i> , 2020, 3, 137-142.	0.4	0
39	Ab locks for improving the selectivity and safety of antibody drugs. <i>Journal of Biomedical Science</i> , 2020, 27, 76.	2.6	18
40	Metastatic Thymoma Harboring a Deleterious <i>BRCA2</i> Mutation Derives Durable Clinical Benefit from Olaparib. <i>Oncologist</i> , 2020, 25, 301-305.	1.9	9
41	The role of growth factor receptors in viral infections: An opportunity for drug repurposing against emerging viral diseases such as COVID-19?. <i>FASEB BioAdvances</i> , 2020, 2, 296-303.	1.3	50
42	Recent advances in nanoscale materials for antibody-based cancer theranostics. <i>Biosensors and Bioelectronics</i> , 2021, 173, 112787.	5.3	12
43	Next-Generation Immunotherapies to Improve Anticancer Immunity. <i>Frontiers in Pharmacology</i> , 2020, 11, 566401.	1.6	8
44	A case of trastuzumab-induced dermatomyositis. <i>Journal of Cancer Research and Therapeutics</i> , 2021, 17, 1112.	0.3	4
45	Gut Microbiota Condition the Therapeutic Efficacy of Trastuzumab in HER2-Positive Breast Cancer. <i>Cancer Research</i> , 2021, 81, 2195-2206.	0.4	63
46	Advancements in mRNA Encoded Antibodies for Passive Immunotherapy. <i>Vaccines</i> , 2021, 9, 108.	2.1	34
47	Recent progress in immunotherapy of breast cancer targeting the human epidermal growth factor receptor 2 (HER2). <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 1235-1244.	0.5	6
48	Monoclonal antibody-based cancer therapies. <i>Chinese Journal of Chemical Engineering</i> , 2021, 30, 301-307.	1.7	7
49	Targeting MYC: From understanding its biology to drug discovery. <i>European Journal of Medicinal Chemistry</i> , 2021, 213, 113137.	2.6	17
50	Treatment outcomes among human epidermal growth factor receptor 2 positive breast cancer patients: A systematic review. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 1468-1476.	0.5	1
51	Effects of Lapatinib on HER2-Positive and HER2-Negative Canine Mammary Carcinoma Cells Cultured In Vitro. <i>Pharmaceutics</i> , 2021, 13, 897.	2.0	3
52	The predictive potential of Neuronatin for neoadjuvant chemotherapy of breast cancer. <i>Cancer Biomarkers</i> , 2021, 32, 161-173.	0.8	2
53	HER2-antigen-specific humoral immune response in breast cancer lymphocytes transplanted in hu-PBL hIL-4 NOG mice. <i>Scientific Reports</i> , 2021, 11, 12798.	1.6	4
54	Exosome-mediated transfer of circHIPK3 promotes trastuzumab chemoresistance in breast cancer. <i>Journal of Drug Targeting</i> , 2021, 29, 1004-1015.	2.1	16

#	ARTICLE	IF	CITATIONS
55	Molecular docking and ADMET studies to predict the anti-breast cancer effect of aloin by targeting estrogen and progesterone receptors. <i>Materials Today: Proceedings</i> , 2023, 80, 2378-2384.	0.9	2
56	Valproic Acid and Breast Cancer: State of the Art in 2021. <i>Cancers</i> , 2021, 13, 3409.	1.7	30
57	Current state and comparison of the clinical development of bevacizumab, rituximab and trastuzumab biosimilars. <i>Future Oncology</i> , 2021, 17, 2529-2544.	1.1	8
58	Real-world effectiveness of post-trastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: a retrospective observational study (KBCSG-TR 1917). <i>BMC Cancer</i> , 2021, 21, 795.	1.1	3
59	Cancer immunotherapy from biology to nanomedicine. <i>Journal of Controlled Release</i> , 2021, 336, 410-432.	4.8	12
60	Pharmacological Basis of Breast Cancer Resistance to Therapies - An Overview. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 760-774.	0.9	1
61	Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review. <i>Cancers</i> , 2021, 13, 4287.	1.7	441
62	Multi-Parametric MRI-Based Radiomics Models for Predicting Molecular Subtype and Androgen Receptor Expression in Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 706733.	1.3	39
63	Metastatic Breast Cancer, Organotropism and Therapeutics: A Review. <i>Current Cancer Drug Targets</i> , 2021, 21, 813-828.	0.8	6
64	An update of the molecular mechanisms underlying doxorubicin plus trastuzumab induced cardiotoxicity. <i>Life Sciences</i> , 2021, 280, 119760.	2.0	23
65	Anticancer Effects and Mechanisms of OSW-1 Isolated From <i>Ornithogalum saundersiae</i> : A Review. <i>Frontiers in Oncology</i> , 2021, 11, 747718.	1.3	6
66	Extracellular production of an anti-HER2 single-chain variable antibody fragment in <i>Escherichia coli</i> . <i>Process Biochemistry</i> , 2021, 111, 87-94.	1.8	5
67	The effects of anticancer therapies on bone metastases in breast cancer. , 2022, , 987-1002.		0
68	Bone-Targeted Drug Delivery Systems and Strategies for Treatment of Bone Metastasis. <i>Chemical and Pharmaceutical Bulletin</i> , 2020, 68, 560-566.	0.6	24
69	A novel fully human anti-NCL immunoRNase for triple-negative breast cancer therapy. <i>Oncotarget</i> , 2016, 7, 87016-87030.	0.8	23
70	Exosomal lncRNAs: the newest promising liquid biopsy. , 2019, 2, 1002-1017.		9
71	Folic Acid Conjugated Nanocarriers for Efficient Targetability and Promising Anticancer Efficacy for Treatment of Breast Cancer: A Review of Recent Updates. <i>Current Pharmaceutical Design</i> , 2020, 26, 5365-5379.	0.9	12
72	Antibody-Antineoplastic Conjugates in Gynecological Malignancies: Current Status and Future Perspectives. <i>Pharmaceutics</i> , 2021, 13, 1705.	2.0	11

#	ARTICLE	IF	CITATIONS
73	ESE-1 Knockdown Attenuates Growth in Trastuzumab-resistant HER2+ Breast Cancer Cells. <i>Anticancer Research</i> , 2017, 37, 6583-6591.	0.5	8
74	Novel Target Sites for Drug Screening: A Special Reference to Cancer, Rheumatoid Arthritis and Parkinson's Disease. <i>Current Signal Transduction Therapy</i> , 2019, 14, 107-121.	0.3	0
75	SYNTHESIS OF TAMOXIFEN DERIVATIVES AND THEIR BIOLOGICAL ACTIVITIES. <i>Plant Archives</i> , 2020, 21, .	0.1	0
76	Immunotherapy and Radiosurgery. , 2020, , 423-436.		0
77	Al[¹⁸ F]-AEEA-HER2-BCH Affibody PET Imaging Accurately Depict HER2 Positive Lesions. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
78	Actively Targeted Nanomedicines in Breast Cancer: From Pre-Clinical Investigation to Clinic. <i>Cancers</i> , 2022, 14, 1198.	1.7	29
79	Cathepsin B-A Neuronal Death Mediator in Alzheimer's Disease Leading to Neurodegeneration. <i>Mini-Reviews in Medicinal Chemistry</i> , 2022, 22, 2012-2023.	1.1	8
80	An Introduction to Biosimilars for the Treatment of Retinal Diseases: A Narrative Review. <i>Ophthalmology and Therapy</i> , 2022, 11, 959-982.	1.0	12
81	Trastuzumab in Breast Cancer Treatment: The Era of Biosimilars. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 2507-2516.	0.9	1
82	Value of CT-Based Radiomics in Predicating the Efficacy of Anti-HER2 Therapy for Patients With Liver Metastases From Breast Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 852809.	1.3	3
83	Computational Pathways Analysis and Personalized Medicine in HER2- Positive Breast Cancer. <i>Current Pharmacogenomics and Personalized Medicine</i> , 2022, 19, .	0.2	0
84	A triple enhanced permeable gold nanoraspberry designed for positive feedback interventional therapy. <i>Journal of Controlled Release</i> , 2022, 345, 120-137.	4.8	6
85	Fluorescence, UV-Vis and Molecular Docking Studies on Trastuzumab-Ligand Interactions. , 2021, , .		0
86	ICAM-1 Targeted Drug Combination Nanoparticles Enhanced Gemcitabine-Paclitaxel Exposure and Breast Cancer Suppression in Mouse Models. <i>Pharmaceutics</i> , 2022, 14, 89.	2.0	8
88	Cholesterol and Its Derivatives: Multifaceted Players in Breast Cancer Progression. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	11
89	Differential Gene Analysis of Trastuzumab in Breast Cancer Based on Network Pharmacology and Medical Images. <i>Frontiers in Physiology</i> , 0, 13, .	1.3	2
90	The interaction between the soluble programmed death ligand-1 (sPD-L1) and PD-1+ regulator B cells mediates immunosuppression in triple-negative breast cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
91	Optimize the combination regimen of Trastuzumab and Nab-paclitaxel in HER2-positive tumors via modulating Caveolin-1 expression by lovastatin. <i>Asian Journal of Pharmaceutical Sciences</i> , 2022, 17, 697-712.	4.3	3

#	ARTICLE	IF	CITATIONS
92	Exosomes: Small Vesicles with Important Roles in the Development, Metastasis and Treatment of Breast Cancer. <i>Membranes</i> , 2022, 12, 775.	1.4	6
93	Reassessing vascular endothelial growth factor (VEGF) in anti-angiogenic cancer therapy. <i>Cancer Treatment and Research Communications</i> , 2022, 32, 100620.	0.7	23
94	The role of CircRNA/miRNA/mRNA axis in breast cancer drug resistance. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	11
95	Current Molecular Combination Therapies Used for the Treatment of Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11046.	1.8	19
96	Five hub genes contributing to the oncogenesis and trastuzumab-resistance in gastric cancer. <i>Gene</i> , 2023, 851, 146942.	1.0	5
97	A gene expression signature in HER2+ breast cancer patients related to neoadjuvant chemotherapy resistance, overall survival, and disease-free survival. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	2
98	Blood metabolomes as non-invasive biomarkers and targets of metabolic interventions for doxorubicin and trastuzumab-induced cardiotoxicity. <i>Archives of Toxicology</i> , 2023, 97, 603-618.	1.9	2
99	Notch signaling pathway: a comprehensive prognostic and gene expression profile analysis in breast cancer. <i>BMC Cancer</i> , 2022, 22, .	1.1	10
100	Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis. <i>Systematic Reviews</i> , 2022, 11, .	2.5	4
101	Breast cancer heterogeneity and its implication in personalized precision therapy. <i>Experimental Hematology and Oncology</i> , 2023, 12, .	2.0	31
102	Development of a Modular NTA:His Tag Viral Vaccine for Co-delivery of Antigen and Adjuvant. <i>Bioconjugate Chemistry</i> , 2023, 34, 269-278.	1.8	6
103	HER2/neu-based vaccination with li-Key hybrid, GM-CSF immunoadjuvant and trastuzumab as a potent triple-negative breast cancer treatment. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 6711-6718.	1.2	2
105	Research Progress on Bioactive Metal Complexes against ER-Positive Advanced Breast Cancer. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 2235-2256.	2.9	3
106	Antioxidant Protection against Trastuzumab Cardiotoxicity in Breast Cancer Therapy. <i>Antioxidants</i> , 2023, 12, 457.	2.2	3
107	Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario. <i>Pharmaceutics</i> , 2023, 15, 664.	2.0	2
108	Synergistic Combinatorial effect of L-asparaginase and Trastuzumab against HER2+ breast cancer cells. <i>Research Journal of Pharmacy and Technology</i> , 2022, , 5819-5824.	0.2	0
109	The Role of Theragnostics in Breast Cancer: A Systematic Review of the Last 12 Years. <i>Current Medical Imaging</i> , 2023, 19, .	0.4	1
110	Cardiotoxicity from neoadjuvant targeted treatment for breast cancer prior to surgery. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	1

#	ARTICLE	IF	CITATIONS
111	A Review and Meta-analysis on Trastuzumab Resistance in Patients with HER2+ Breast Cancer. Mini-Reviews in Medicinal Chemistry, 2023, 23, .	1.1	0
112	Cellular 1H MR Relaxation Times in Healthy and Cancer Three-Dimensional (3D) Breast Cell Culture. International Journal of Molecular Sciences, 2023, 24, 4735.	1.8	0
113	Detailed curriculum vitae of HER2-targeted therapy. , 2023, 245, 108417.		4
116	The major clinical components of cancer immunotherapy (modulating cell-mediated immune) Tj ETQq1 1 0.784314 rgBT /Overlock 10		0
124	Role of EGFR and FASN in breast cancer progression. Journal of Cell Communication and Signaling, 2023, 17, 1249-1282.	1.8	3
141	Case report: Urothelial injury in a female with breast cancer: a rare adverse event after the combination of paclitaxel and trastuzumab. Frontiers in Oncology, 0, 13, .	1.3	0